Taking people in United StatesPhase 1

FET-PET/MRI scans to find small hormone-producing pituitary tumors

Tests FET-PET/MRI imaging to find pituitary adenomas that standard MRI misses.

Key facts

Who runs it: Mayo Clinic
Where: Jacksonville, United StatesSee the site
Trial code: NCT07456878
Registry title: Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
Status: Recruiting
Phase: Phase 1
People taking part: 5 people, planned
Started: 8 Jan 2026
Expected to end: Dec 2026
Type of study: Interventional
Treatments tested: FET-PET/MRI
Record updated: 9 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a hormone-making pituitary tumour that a standard MRI scan could not clearly find. It tests a FET-PET/MRI scan to locate the tumour.

Age: 18 to 75 years
Sex: All sexes
Disease stage: Hormone-making pituitary tumour (Cushing's disease, acromegaly, or prolactin excess from a tumour), new or come back after treatment. The tumour was not seen or unclear on a DCE-MRI scan.
Earlier treatment: People must be willing to have surgery if a tumour is found, or already be scheduled for surgery.
Biomarker or test result: Blood or hormone tests must prove Cushing's disease, acromegaly or prolactin excess from a tumour. Women who can become pregnant need a negative urine pregnancy test ≤48 hours before the 18F-FET injection.

Main reasons for not taking part

Reasons you cannot have an MRI or PET scan
Known allergy to contrast agents or other scan materials
Severe health problems, such as being unable to lie on your back for 30-60 minutes
The tumour was already clearly found on MRI

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines
Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor
Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful
Able to provide informed consent and be capable of completing the imaging protocols
Female subjects of childbearing potential (women of childbearing potential [WOCBP]) must have a negative urine pregnancy test ≤48 hours prior to the 18F-FET injection

Who cannot take part

Patients with known allergies to contrast agents or other imaging-related materials
Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes)
Patients with contraindications to MRI or PET scans
Patients with successful MRI localization of the adenoma

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 75 years old?

Where in United States

Mayo ClinicJacksonville, United StatesContact: Julia SantosTaking people

About the trial

What the trial wants to find out

The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.

The group in the trial

FET-PET/MRITreatment being tested
Patients who desire surgery and have active Cushing's Disease, Acromegaly, or tumoral hyperprolactinemia, occult tumor on DCE-MRI